Effect of FLT3 ligand on survival and disease phenotype in murine models harboring a FLT3 internal tandem duplication mutation

Comparative Medicine

Volumn 63, Issue 3, 2013, Pages 218-226

  Bailey, Emily J ^a   Duffield, Amy S ^a   Greenblatt, Sarah M ^a   Aplan, Peter D ^b   Small, Donald ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Acute myeloid leukemia; FL; AML; FLT3 ligand; FLT3; FMS like tyrosine kinase 3; ITD; Internal tandem duplication; MPN; Myeloproliferative neoplasm

Indexed keywords

FLT3 LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; IN VIVO STUDY; LATENT PERIOD; LEUKEMIA CELL; LEUKEMOGENESIS; LYMPHOID CELL; MOUSE; MYELOID LEUKEMIA; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; BASE SEQUENCE; DNA PRIMERS; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; HUMANS; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MUTATION; PHENOTYPE;

EID: 84879341079     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Animal Welfare Act as Amended. 2008. 7 USC §2131-2159.
2. Bojko P, Pawloski D, Stellberg W, Schroder JK, Seeber S. 2002. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-GCSF, lenograstim) and after high-dose chemotherapy. Ann Hematol 81:522-528. (Pubitemid 36075505)
3. Cheon DJ, Orsulic S. 2011. Mouse models of cancer. Annu Rev Pathol 6:95-119.
4. Choudhary C, Muller-Tidow C, Berdel WE, Serve H. 2005. Signal transduction of oncogenic Flt3. Int J Hematol 82:93-99. (Pubitemid 41233166)
5. Frese KK, Tuveson DA. 2007. Maximizing mouse cancer models. Nat Rev Cancer 7:645-658. (Pubitemid 47327410)
6. Gilliland DG, Griffin JD. 2002. The roles of FLT3 in hematopoiesis and leukemia. Blood 100:1532-1542. (Pubitemid 34925124)
7. Greenblatt S, Li L, Slape C, Nguyen B, Novak R, Duffield A, Huso D, Desiderio S, Borowitz MJ, Aplan P, Small D. 2012. Knock-in of a FLT3-ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model. Blood 119:2883-2894.
8. Levis M. 2011. FLT3-ITD AML and the law of unintended consequences. Blood 117:6987-6990.
9. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD. 2011. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 117:3294-3301.
10. Li L, Bailey E, Greenblatt S, Huso D, Small D. 2011. Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3-ITD knockin mice. Blood 118:4935-4945.
11. Li L, Piloto O, Nguyen HB, Greenberg K, Takamiya K, Racke F, Huso D, Small D. 2008. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood 111:3849-3858.
12. Lin YW, Slape C, Zhang Z, Aplan PD. 2005. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood 106:287-295. (Pubitemid 40967204)
13. Lyman SD, Jacobsen SE. 1998. c-Kit ligand and Flt3 ligand: stem-progenitor cell factors with overlapping yet distinct activities. Blood 91:1101-1134. (Pubitemid 28086863)
14. Marchetto S, Fournier E, Beslu N, Aurran-Schleinitz T, Dubreuil P, Borg JP, Birnbaum D, Rosnet O. 1999. SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. Leukemia 13:1374-1382. (Pubitemid 29429764)
15. McCormack E, Bruserud O, Gjertsen BT. 2008. Review: genetic models of acute myeloid leukaemia. Oncogene 27:3765-3779. (Pubitemid 351862057)
16. McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, Maraskovsky E, Maliszewski CR, Lynch DH, Smith J, Pulendran B, Roux ER, Teepe M, Lyman SD, Peschon JJ. 2000. Mice lacking Flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95:3489-3497. (Pubitemid 30428482)
17. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S. 1996. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1911-1918. (Pubitemid 27019637)
18. Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O'Brien S, Koller C, Pierce S, Brandt M, Kennedy D, Cortes J, Beran M. 2010. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res 34:752-756.
19. Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE. 2000. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the FLT3 gene. Leukemia 14:675-683. (Pubitemid 30195459)
20. Rosnet O, Buhring HJ, deLapeyriere O, Beslu N, Lavagna C, Marchetto S, Rappold I, Drexler HG, Birg F, Rottapel R, Hannum C, Dubreuil P, Birnbaum D. 1996. Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematol 95:218-223. (Pubitemid 26000216)
21. Sato T, Yang X, Knapper S, White P, Smith BD, Galkin S, Small D, Burnett A, Levis M. 2011. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 117:3286-3293.
22. Shih LY, Huang CF, Wu JH, Lin TL, Dunn P, Wang PN, Kuo MC, Lai CL, Hsu HC. 2002. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 100:2387-2392.
23. Small D. 2006. FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program 2006:178-184.
24. Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, Witte L, Burrow C, Ratajczak MZ, Gewirtz AM, Civin CI. 1994. STK1, the human homolog of Flk2/Flt3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor-stem cells. Proc Natl Acad Sci USA 91:459-463. (Pubitemid 24041421)
25. Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J, Slovak ML, Willman CL, Radich JP. 2006. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood 107:3724-3726.
26. Stirewalt DL, Radich JP. 2003. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3:650-665. (Pubitemid 37328820)
27. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. 2008. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon (France): International Agency for Research on Cancer (IARC).
28. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, Ehninger G, Illmer T. 2002. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335. (Pubitemid 34627197)
29. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, Carroll AJ, Mrozek K, Vardiman JW, George SL, Kolitz JE, Larson RA, Bloomfield CD, Caligiuri MA. 2001. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res 61:7233-7239. (Pubitemid 32946520)
30. Wodnar-Filipowicz A, Lyman SD, Gratwohl A, Tichelli A, Speck B, Nissen C. 1996. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood 88:4493-4499. (Pubitemid 26419132)
31. Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, Spolski R, Leonard WJ, Broxmeyer HE. 2000. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med 192:719-728.
32. Zhang S, Mantel C, Broxmeyer HE. 1999. Flt3 signaling involves tyrosyl phosphorylation of SHP2 and SHIP and their association with Grb2 and Shc in Baf3-Flt3 cells. J Leukoc Biol 65:372-380. (Pubitemid 29109711)
33. Zheng R, Bailey E, Nguyen B, Yang X, Piloto O, Levis M, Small D. 2011. Further activation of FLT3 mutants by FLT3 ligand. Oncogene 30:4004-4014.
34. Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG, Poon LF, Xie Z, Palaniyandi S, Yu H, Glaser KB, Albert DH, Davidsen SK, Chen CS. 2009. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 113:4052-4062.
35. Zwierzina H, Anderson JE, Rollinger-Holzinger I, Torok-Storb B, Nuessler V, Lyman SD. 1999. Endogenous FLT3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes. Leukemia 13:553-557. (Pubitemid 29195283)